Serelaxin in addition to standard therapy in acute heart failure: rationale and design of the RELAX‐AHF‐2 study

Patients admitted for acute heart failure (AHF) experience high rates of in‐hospital and post‐discharge morbidity and mortality despite current therapies. Serelaxin is recombinant human relaxin‐2, a hormone with vasodilatory and end‐organ protective effects believed to play a central role in the car...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Eur J Heart Fail
Main Authors: Teerlink, John R., Voors, Adriaan A., Ponikowski, Piotr, Pang, Peter S., Greenberg, Barry H., Filippatos, Gerasimos, Felker, G. Michael, Davison, Beth A., Cotter, Gad, Gimpelewicz, Claudio, Boer‐Martins, Leandro, Wernsing, Margaret, Hua, Tsushung A., Severin, Thomas, Metra, Marco
Format: Artigo
Sprog:Inglês
Udgivet: John Wiley & Sons, Ltd 2017
Fag:
Trial Design
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5488179/
https://ncbi.nlm.nih.gov/pubmed/28452195
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.830
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker